VXRT(Delisted)
VaxartยทNASDAQ
--
--(--)
VXRT Profile
Vaxart, Inc.
A biotech company developing oral vaccines for infectious diseases and cancer
170 Harbor Way, Suite 300, South San Francisco, California 94080
--
Vaxart, Inc., is a company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antiviral drugs. Vaxart's oral vaccine is designed to generate a broad and long-lasting immune response, protect against a variety of infectious diseases, and can be used to treat chronic viral infections and cancer. Vaxart's oral vaccine is administered in convenient room-temperature stable tablets, not by injection. Vaxart believes that the tablet vaccine is easier to distribute and take than the injection vaccine, and can significantly improve vaccination rates. Vaxart's development plans include oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV) and therapeutic vaccines for human papillomavirus (HPV). Through the acquisition of other companies, Vaxart has also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma acuminatum caused by HPV virus types 6 and 11.
